OGT expands NGS cancer panel offering

Create PDF

The SureSeq Breast Cancer plus CNV panel detects indels, SNVs, and CNVs and offers 100 percent concordance with multiplex ligation-dependent probe amplification. The panel targets BRCA1, BRCA2, ATM, TP53, CHEK2, PALB2, and PTEN and is able to detect CNVs ranging from single exons to full gene deletions and duplications.

The panels have been designed based on the most recent literature, the company reports, and with input from recognized cancer experts.